FDA Approves First mRNA Flu Vaccine, Moderna's mFlusiva, for Adults Over 50

Science

6 August 2026 at 10:03 pm

FDA Approves First mRNA Flu Vaccine, Moderna's mFlusiva, for Adults Over 50

HyperFast News

Summary

The U.S. Food and Drug Administration (FDA) has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, for individuals aged 50 and older. This new vaccine demonstrated up to 27% greater effectiveness than traditional flu shots in a study and offers advantages in rapid development and strain matching, marking a significant milestone in public health.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.